Statement by Mr. François Hollande, President of the Republic, on the fight against cancer, in Paris on February 4, 2014.

France François Hollande · President of France

4 February 2014 · Fight against cancer statement · Paris, France

Context
Hollande addressed health officials and cancer organizations in Paris on February 4, 2014, to present the orientations of France's third Cancer Plan.
Main themes
Fight against cancer, cancer screening, health inequalities, Cancer Plan III, cancer research and treatment, vaccination against cervical cancer, colorectal and breast cancer screening, social and territorial disparities, cancer mortality reduction, public health policy, patient access to care
Duration
~40 min
90th percentile
Words
4,744
90th percentile
Sentences
261
94th percentile
Readability
52
67th percentile
Grade
10.6
27th percentile
Syntax
2.85
28th percentile
Vocabulary
2.12
31st percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 76%75%
  • Economic 16%16%
  • Institutional 4%4%
  • Ceremonial 3%3%
  • Geopolitical 1%1%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 0%

261 sentences in 77 paragraphs

Ladies and gentlemen ministers,

Madam President of the National Cancer Institute,

Ladies and gentlemen directors of organizations,

Ladies and gentlemen,

The fight against cancer is one of the great causes that unites us, that brings us together, beyond sensitivities, divisions, and alternations. And how could it be otherwise? Every year, 150,000 people die from cancer, and 350,000 learn that they have it. Five million families in France are affected, or have been affected, by the disease. And cancer remains the leading cause of mortality.

Behind the dryness of these figures, the anonymity of these statistics, there are lives that suddenly change, perhaps ours one day, that of a parent, a friend, a loved one, and that is why the fight against cancer is a reality now experienced by all. It is therefore quite legitimately that it has also become, for a decade, a shared policy by all.

And the illustration that can be given is precisely the Cancer Plan. The first of these plans, in 2003, laid the foundations of a comprehensive policy by creating the INCa. I want to acknowledge its president, Agnès BUZYN, and beyond her, all the teams that have succeeded one another since the creation of the institute. This first plan generalized the screening of two cancers. It has already raised awareness about the risks of tobacco and has given an impetus to research. The second plan, in 2009, integrated quality criteria into the certification of establishments. It supported innovations and developed clinical trials.

It has been decided to create a third plan. This is the one we will today, not debate the conclusions, but present the orientations. The merit of this work, of these successive plans, has been to create a community - yours - of professionals, activists, volunteers, united around patients and their loved ones, who work every day to alleviate suffering, pain, and to heal.

I would like to thank this entire community here, and more particularly the League Against Cancer and the ARC Foundation, for the remarkable work that these associations accomplish. After ten years of efforts, the results are here. Thanks to research, thanks to medicine, it has been proven that it is possible to cure cancer, as now, this is the case for one in two patients, and this is a considerable factor of hope. But these undeniable advances must not hide the harsh reality: the number of people affected by cancer continues to rise, and inequalities among the French are worsening. Thus, the risk of dying from cancer between the ages of 30 and 65 is twice as high among workers as among executives.

These inequalities concern screening, access to treatments, life during and after cancer, and exposure to risks. These inequalities are social, generational, and also territorial. That is why this third plan for the fight against cancer has set itself the objective and ambition of giving the same chances to everyone, everywhere in France, to heal from cancer.

I want to thank Professor Jean-Paul VERNANT, who coordinated the preparation of this plan, and all the teams that surrounded him. The presentation today of this plan commits us, commits the public authorities, commits all actors in the fight against cancer.

The first objective we set for ourselves is to cure more patients.

Everything starts with screening. It currently concerns breast cancer and colorectal cancer. But the campaigns launched in recent years struggle to reach those who are most vulnerable. Less than two-thirds of women are screened for breast cancer. And this proportion falls below one-third for those concerned with colorectal cancer. This situation increases inequalities, and correcting it will be a priority of the third Cancer Plan by giving it a new dimension. Thus, we will help the most modest to access screening and the complementary examinations that follow by ensuring them complete coverage without upfront costs.

In the same way, specific follow-up for individuals with personal or family histories of cancer will be established.

Cervical cancer will also, and this is one of the announcements of the Cancer Plan, be subject to systematic screening. This cancer currently affects 3,000 women and causes more than 1,000 deaths each year. Therefore, the generalization of the smear test every three years for 80% of women, compared to 60% today, will reduce mortality by 30% in ten years.

Cervical cancer is the only one, I say the only one, for which there is a vaccine, and yet, in France, this vaccine is administered to only 30% of young girls. This is a new source of inequalities. Of course, I am aware of the reservations raised by poorly designed vaccination campaigns, but this vaccine has proven its effectiveness. Therefore, within five years, we will double the vaccination coverage against cervical cancer, which will allow for its eventual eradication.

After screening, there is diagnosis. Here too, any delay is a risk, any lost time can be fatal. In France, the average waiting time for an MRI examination is 27 days. This figure alone could satisfy us, but in fact, it varies from one to two depending on the place of residence. How can we accept that? The third Cancer Plan will set as an obligation that the waiting time does not exceed twenty days, regardless of where one resides. And we will provide the means for this, as fifteen million euros will be allocated to regions that are currently under-equipped.

Finally, some cancers are all the more difficult to identify because they are rare, and therefore require expertise that not all practitioners have necessarily acquired. This is particularly the case for rare adult cancers and solid tumors in children. In these situations, a second opinion, a second expertise will be required, and here too, this is an inequality that will fall.

After screening, after diagnosis, there is treatment. The first requirement is the information of patients who must be able to know and compare the performance of the establishments and services to which they turn.

That is why new quality indicators will be established; they will be made public by the Ministry of Health, on the national health information website, which our country has been waiting for a long time. This will be a major advance for the rights of patients, for health democracy, and it goes well beyond the fight against cancer.

Reducing inequalities in treatment also means ensuring that technological and therapeutic advances spread at the same pace across the territory.

Because cancer treatment is no longer just chemotherapy or major surgery; it is also, increasingly, oral chemotherapy, which can be administered at home; it is interventional radiology; it is especially outpatient surgery, which will concern one in two patients operated on for breast cancer within ten years. This technical revolution, because it is one, also requires a profound change in the very organization of our healthcare system, that is to say, the introduction of a pathway medicine that will be based on the personalization of the response.

How to achieve this? First, by sharing information among all healthcare professionals, whether they work in hospitals or in the community. A communicable cancer dossier will therefore be created. It will contain all data related to the patient's history and treatments throughout the care pathway. By the end of 2015, all patients will have access to it - this is also an advance of the third Cancer Plan.

The personalization of the response also calls for better coordination between the hospital, which has a central role today, and the attending physician, who must occupy an increasingly prominent place in the individual follow-up of the patient, as the latter will increasingly be treated outside major healthcare establishments.

This new organization also requires recognizing new professions to support patients, to create new functions. That is why a Master's level clinical nurse diploma will be created starting from the 2016 academic year. Similarly, radiophysicists and dosimetrists, who both perform essential missions, will be fully recognized as health professions.

In short, it is clear that cancer treatment will profoundly change the organization of our healthcare system. This is the first objective of the Cancer Plan: to cure more patients.

The second objective, still with this perspective of fighting against inequalities, but also of fighting against the disease, is to bring innovations to patients even more quickly.

Research must first focus on the essentials. This is fundamental research, and it will be preserved: the State will guarantee a funding level of at least 50% of the credits for project calls from INCa and Aviesan. This is a necessary condition to ensure that teams have the independence they need to carry out their work over the long term.

Alongside this fundamental research, there is clinical research, which must be deployed for the benefit of all patients. Clinical trials currently involve 25,000 patients. The challenge of the Cancer Plan is to double the number of clinical trials in five years so that they concern all cancers - and notably the 1,700 pediatric cancers, and all regions, especially those that are currently the least involved, I am thinking of overseas territories.

The ambition of the Cancer Plan will be to implement a major innovation, one that can indeed revolutionize cancer treatment, I am talking about the contribution of genetics. It will particularly help to cure cancers that are currently the most resistant.

The analysis of genetic factors has indeed become a determining element of diagnosis, but also the basis for targeted therapies specific to each type of tumor. These practices, however, are still too limited. The Cancer Plan will allow these analyses to be offered to several tens of thousands of patients each year. We are going to launch a unique program in the world due to its scale. It involves high-throughput sequencing of all cancers. What is the challenge? To provide a complete view of the genome of each tumor. And thanks to this, to offer patients personalized care.

It is always the same approach, to individualize cancer treatment as much as possible. From 10,000 tumors analyzed in 2015, the goal is to reach 60,000 in 2018. We will again allocate the necessary means, as this program is exceptional: 60 million euros will be allocated over the duration of the plan.

But if I want to take a more general consideration, and even beyond these techniques, we are entering a period where therapeutic advances will multiply - and that is good, it is a sign of hope. What is the problem we encounter? It is that these advances can benefit patients without delay. However, we know that there are particularly cumbersome procedures - evaluations, authorizations, pricing - which risk delaying patients' access to the care they demand, and to the therapeutic advances that are possible.

Therefore, everything will be done to accelerate procedures and prescribe innovative drugs without waiting for market authorization. Similarly, the possibilities for extending the indications for use of a product will be relaxed when it proves effective for treating other types of tumors. Why wait, why open a new procedure, since this can allow for immediate healing?

The other challenge of these advances and innovations, we all have it in mind, is the price. The arrival of new products leads to a surge in treatment costs, which I remind you are borne by Health Insurance. This is still a guarantee that we must provide to all our fellow citizens. It is out of the question to deprive patients of the progress of science because it would be too expensive.

But this ambition - to treat, to treat regardless of the cost - assumes that we are particularly vigilant in setting the price of medications at a level that corresponds to the reality of their therapeutic contribution, and then periodically regulating them, based on their use and the quality of life they provide. In other words, why should we continue to pay a high price for a product whose medical interest has become lesser due to other innovations that have been announced? Yes, if we want to meet the challenge of both access to therapeutic innovations for all and controlling costs and prices, then we must fight against excesses, we must combat situations of rent-seeking, and accompany therapeutic advances at controlled prices. This is also the challenge of the Cancer Plan.

The third priority is to improve the lives of patients.

Three million people have cancer in France, or have recovered from it. They have rights and want to be fully considered and recognized. Respect, evidently, applies to the announcement of the disease, which now meets strict conditions. But this requirement must spread to all stages of treatment, up to recovery, especially when the primary care physician takes over from the hospital. However, this moment is often overlooked, even though it does not mark the end of the journey. That is why a personalized post-cancer program will be introduced, which will specify any follow-up care, the frequency of check-ups, and the modalities of support.

But there is another issue, which is to allow the patient to maintain their place, their full place, in society.

I will start with children. There are 1,700 in France who are affected by cancer each year. They must be able to continue their studies, despite the treatments. When schooling becomes impossible, access to correspondence courses must be guaranteed. But it must also be free. It will be, as the free enrollment in CNED will be extended to all students over 16 years old who have cancer. It is the right to be able to learn, regardless of the illness.

And then there are adults, who must also continue their professional activity. However, we know very well that one-third of working people, at the time their diagnosis is delivered, lose their jobs after 2 years. This is unacceptable. Therefore, we must promote flexible working hours for people with cancer, establish enhanced rights in terms of professional training, raise awareness among companies about the risks of discrimination, and the conditions for returning to work. These are all avenues we are opening with the Cancer Plan. And I have tasked the Minister of Labor with implementing these guidelines with social partners.

But there are also situations where it is no longer possible to continue a professional activity due to the illness. Thus, the pain of cancer is compounded by job insecurity. For people who have worked less than 200 hours in a quarter, there are no daily allowances. That is why the government has decided to lower this threshold to 150 hours starting January 1, 2015, particularly for people with cancer. Always the same idea: reduce inequalities.

It is this same will that must also lead us to make it possible, for all patients, or those who have been, to have breast or dental reconstruction procedures. However, today the "out-of-pocket expenses," as they say, that is to say what must be paid by patients, remain too high. We will ensure that the application of amendment number 8 of the medical convention on excess fees is strictly respected for cancer patients.

I will go further. At the end of the Plan, a reconstructive surgery offer will be created in each region, accessible to all, at no cost to patients. The Regional Health Agencies will have to organize this right, to be able to be fully, not only treated, but cared for until the end, so that no trace of the disease remains on the body.

Finally, there is life after cancer. I happily remind you, with hope: the majority of cancer patients are cured or will be cured. But, at the same time, another fatality falls upon them: they are cured, science demonstrates it. But they remain suspect, and they discover this when, wanting to apply for credit, they are asked for more guarantees, or to bear more costs. So, they are cured, but they can no longer be homeowners, or only at exorbitant costs.

I know that for the past 10 years what is called the AERAS convention concluded between the State, insurers, and patient associations has improved access to credit for people who have been affected, particularly by cancer. But, here too, let us face the facts: the system has not evolved while many former patients have a life expectancy exactly comparable to those who have not been ill.

The time has come to establish a true right to be forgotten. It will apply to all those who, as children or adolescents, have overcome cancer, as well as to all other patients whose scientific data tell us they are definitively cured. The convention will be renegotiated on these bases, and if it is not possible to conclude it this way, the law will intervene.

The last ambition, I would even say the strongest, that we must carry through this Cancer Plan, is quite simple: to prevent cancer.

Because cancer is an avoidable disease, in a large part of cases. The report that was given to me suggests that 80,000 cancers could be avoided if everything were done. Every year, in France, there are 44,000 deaths from cancers related to tobacco, 15,000 related to alcohol, more than 2,000 cancers related to obesity, and 1,000 to sun exposure. In total, 40% of cancer-related mortality is due to risk factors that are themselves avoidable, linked to the environment or behaviors. These cancers are not only too numerous, but they continue to increase.

If we look at countries comparable to ours: in England, the number of lung cancers has been declining for 30 years; in the United States, since 1990, the figures are going in the same direction. This is part of the failure of what has been done for years; this is also the main source of inequality; this is where all our actions must converge. Prevention is the best investment. This applies not only to cancer but to all public health issues. It will therefore be the essential element of the health strategy that will be presented by the Minister of Social Affairs and Health.

But without waiting, the third Plan will include measures on each of the main risks. And particularly on the first. Tobacco is responsible for 30% of cancer deaths. It is the leading cause of mortality for both women and men - but in this regard, equality is progressing, and it is not the best! The second Cancer Plan set a goal of reducing the prevalence of tobacco, that is to say, the number of smokers, from 30% to 20% in the population. The current rate is 33%; there are more smokers than there were 5 years ago.

I have therefore asked Marisol Touraine to present, before the summer, a national program for reducing tobacco use, which will be precisely integrated into the national health strategy. It will be developed by all concerned actors, to act on consumption, which is becoming an addiction. We must use all levers.

The first is price. What does experience reveal to us? It teaches us that the only significant decreases in tobacco consumption have been rare and occurred after strong increases in cigarette prices. This was the case in France in 2003, but only for a few years. What is the situation today? From 2005 to 2012, there were continuous increases, which raised the average price of tobacco by 1.20 euros. 1.20 euros is not negligible, but these increases have been gradual and sometimes designed more to increase state revenues, without being accompanied by the necessary measures to encourage smokers to quit.

Today, the price of tobacco in France has become the highest in continental Europe. And more and more smokers are buying their cigarettes abroad, on the black market, or online. Such is the French paradox: we have some of the highest tobacco prices in Europe, and the highest tobacco consumption in Europe. Therefore, we need to build a strategy in relation to this reality.

Price increases must regain their public health purpose. For the past 18 months, the price of a pack has increased on average by 80 cents, or more than 12%. This movement will continue, but it will be guided by a single imperative: the additional revenues will not benefit the state, but will fund a dedicated fund, that is to say, intended for cancer research, prevention, and improvement of care.

Any action on prices, especially when they are already, as is the case with us, high, can only be conceived within a global strategy that offers smokers real solutions to quit and discourages young people from entering this process. Thus, the second lever is to help smokers quit smoking.

How to do this? First, mobilize health professionals even more, so that they can systematically offer smokers to engage in quitting. Primary care physicians will be encouraged to do so within the framework of public health objectives that contribute, I remind you, to their remuneration. Pharmacists will see their advisory role better defined and recognized within the framework of a negotiation that must be concluded by 2015. Occupational physicians, school nurses, will be authorized to offer nicotine substitutes.

Smokers who want to quit also need specialized and personalized information. Thus, starting next year, there will be a single number to call to be directed to the nearest professional, who will define a personalized smoking cessation program.

Support for the purchase of nicotine substitutes will be increased; the current package is 50 euros, and it has already been raised this year to 150 euros for those under 25. We will extend this measure in 2015 to those aged 25 to 30, to beneficiaries of the Universal Health Coverage, and to all cancer patients. Overcoming cancer is already an objective we must pursue. Quitting tobacco is the condition for not entering cancer. Therefore, quitting tobacco must become increasingly free. This is the challenge of the plan we are presenting. We will involve complementary organizations, which are essential. Support for quitting will be included in the minimum care basket of responsible contracts. In short, the incentive will be particularly strong.

Finally, tobacconists will be encouraged to adapt to what is our goal: the reduction of the number of smokers and to participate more in the development of tobacco substitution means. The national program for reducing tobacco use will contain, and it is legitimate, measures in favor of diversifying their activities.

The third lever to quit tobacco, or more precisely to not start, is deterrence. Starting with providing information, which is as terrible as it is undeniable: a young person who starts smoking, who becomes addicted to tobacco, has, if I may say, a "chance" of 1 in 2 - the word chance is in quotes - of dying before the age of 60. Smoking at 17 means taking the risk of dying before 60!

This sentence must be repeated everywhere and to everyone. This message will therefore be disseminated throughout the country. An information campaign on television will be launched, images will be shown, no matter how harsh, about the ravages of cancer related to tobacco, during prime time, with the largest audience. I remind you that tobacco kills in 15 days what the road, alas, decimates in a year. We will therefore make the same effort, and even more efforts, for these information campaigns on television and on the radio.

We will also exploit the possibilities offered by the recent tobacco directive to strengthen information on packages; we will ensure the effectiveness of the ban on selling tobacco to minors. Minors means under 18 years old. However, we know that there are too many under 18s who are already smokers. We will strengthen the sanctions related to the sale of tobacco products online and we will fight even more effectively against these purchases from abroad, against these traffics, which increasingly concern packs of cigarettes. This is what we will do.

But it is not just tobacco. There is also alcohol, whose consumption among young minors again calls for a doubling of prevention actions. There are cancers related to work, which affect at least 14,000 people each year. Two million are regularly exposed to carcinogenic chemical products. The State will ensure compliance with regulations, and substitution policies will be encouraged with the help of social partners.

Finally, I want to emphasize sun exposure, whose links to skin cancer are evident, as are the risks of ultraviolet radiation. Thus, the use of tanning devices will be more strictly regulated. Everything must be done to inform, to deter, and to also control.

Prevention is the best investment, and this is therefore the ambition of the third Cancer Plan.

I often say when I talk about the future of France, what it must do, what it must be, how it must look to the future: a country only moves forward if it is driven by great causes, its destiny, its influence, its values, its principles, its capacity to have a strong economy, its solidarity, its social model, its rules of life.

A country can only have prospects if the entire national community recognizes itself in what is, at a given moment, the ambition that must unite us. I mentioned it for the economy, for business, because it is the condition for us to remain a strong nation. But I affirm this will also in relation to the fight against cancer, because we have seen that it will determine a new health system, a different organization of care, a different way of living. Overcoming cancer is therefore one of those great objectives to which a nation like ours must dedicate its efforts. Thus, we will conduct research, always striving for excellence, to enable progress.

There is no greater value than progress. We must not simply believe in progress; progress is not a belief. It is the capacity we must have to set it in motion. We must be a nation of progress, and research is an essential part of that.

A country is rightly proud, and we demonstrate this, to guarantee that every patient, regardless of their social condition, age, income, or place of residence, will be treated in the same way, that they will benefit from therapeutic advances like others, that there will be no barriers. Because we are France, and the fight against cancer is part of the embodiment of our values of equality.

The Plan I am presenting will also accelerate personalized medicine and will partially move cancer treatment out of the hospital. We are therefore in the process of inventing this pathway medicine that will likely become the norm tomorrow. The cancer plan also allows for more resources to be allocated to prevention policies, which will be at the heart of the national health strategy.

The Plan I have just presented will mobilize 1.5 billion euros over 5 years, half of which will be dedicated to funding new measures. 1.5 billion, some will say it is too little, surely. Others, who are not ill, may say it is too much. I do not believe so, because everyone can feel concerned.

Overcoming cancer, through this financial mobilization, is making the choice of life, enabling life, gaining life, but it is also about reducing the burdens that weigh on the nation due to cancer. As we evaluate everything, as we calculate everything, it has been indicated that the total cost of cancer burdens for French society, for the health system, amounts to 14 billion euros. And I am not talking about the harm to the lives of patients and their families. 14 billion euros! Overcoming cancer, preventing cancer, is also investing in the future.

This is the challenge we face, as every time we confront a scourge that we must combat. But at the same time, hope is present. Because we have a research system, an organization of care, health professionals, associations. Yes, we can also have hope, because we have the will.

This third Plan engages the State, but it will only have real significance if the professionals you are, the associations you represent, the social organizations you may lead, and more broadly what you represent on behalf of patients, are involved in what we are going to do.

The success of the third Cancer Plan, that is, the reduction of cancer, will depend on this collective mobilization. We are all committed to achieving this objective, which will matter after us. Because we have not finished, even if we must accelerate, go faster, and enable more patients to be cured and prevent others from becoming ill.

Such is our ambition.